Evidence map›Paper›PMID 34389027›Full record

ArticleJournal of orthopaedic surgery and research2021

Temporal response of an injectable calcium phosphate material in a critical size defect.

Jacob T Landeck, William R Walsh, Rema A Oliver, Tian Wang, Mallory R Gordon, Edward Ahn, Colin D White

Open access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jacob T LandeckDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
William R WalshSurgical & Orthopaedic Research Laboratories (SORL), Prince of Wales Clinical School, Level 1 Clinical Sciences Building, Prince of Wales Hospital, UNSW Sydney, Sydney, Australia. w.walsh@unsw.edu.au.ORCID http://orcid.org/0000-0002-5023-6148
Rema A OliverSurgical & Orthopaedic Research Laboratories (SORL), Prince of Wales Clinical School, Level 1 Clinical Sciences Building, Prince of Wales Hospital, UNSW Sydney, Sydney, Australia.
Tian WangSurgical & Orthopaedic Research Laboratories (SORL), Prince of Wales Clinical School, Level 1 Clinical Sciences Building, Prince of Wales Hospital, UNSW Sydney, Sydney, Australia.
Mallory R GordonAnika Therapeutics Inc., Bedford, MA, USA.
Edward AhnX-Factor Capital, Dover, MA, 02030, USA.
Colin D WhiteVertex Pharmaceuticals, 50 Northern Ave, Boston, MA, 02210, USA.
UNSW Sydney · AUCapital University · USUniversity of Massachusetts Chan Medical School · USVertex Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCalcium phosphate-based bone graft substitutes are used to facilitate healing in bony defects caused by trauma or created during surgery. Here, we present an injectable calcium phosphate-based bone void filler that has been purposefully formulated with hyaluronic acid to offer a longer working time for ease of injection into bony defects that are difficult to access during minimally invasive surgery.

methodsThe bone substitute material deliverability and physical properties were characterized, and in vivo response was evaluated in a critical size distal femur defect in skeletally mature rabbits to 26 weeks. The interface with the host bone, implant degradation, and resorption were assessed with time.

resultsThe calcium phosphate bone substitute material could be injected as a paste within the working time window of 7-18 min, and then self-cured at body temperature within 10 min. The material reached a maximum ultimate compressive strength of 8.20 ± 0.95 MPa, similar to trabecular bone. The material was found to be biocompatible and osteoconductive in vivo out to 26 weeks, with new bone formation and normal bone architecture observed at 6 weeks, as demonstrated by histological evaluation, microcomputed tomography, and radiographic evaluation.

conclusionsThese findings show that the material properties and performance are well suited for minimally invasive percutaneous delivery applications.

Indexed as

Bone SubstitutesAnimalsBone RegenerationCalcium PhosphatesFemurRabbitsX-Ray MicrotomographyBone SubstitutesCalcium PhosphatesBone healingCalcium phosphateCementDefectRabbit

Identifiers

PMID34389027
PMCPMC8362253
OpenAlexW3188333090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.